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Abstract
           
Introduction
            We examined the acute effects of neutral endopeptidase inhibitor on the hemodynamics 
and electrical properties of dogs subjected to rapid atrial pacing.                                    
Methods
            Ten beagle dogs were used and divided into two groups with and without candoxatril, a 
neutral endopeptidase inhibitor preadministration.   Before and after the 6 hours rapid atrial 
pacing from the right atrial appendage, the hemodynamics, atrial effective refractory period, and 
monophasic action potential duration of the right atrial appendage were measured and blood 
samples were collected.   Atrial tissue was also excised after the experiment.                    
Results
               Candoxatril significantly increased plasma ANP levels (Control: 88.4 ± 50.25 vs. 
Candoxatril: 197.1 ± 32.09 pg/ml, p = 0.004) and prevented reductions in atrial effective 
refractory period and monophasic action potential duration.  We further demonstrated that the 
treated animals exhibited significantly higher levels of atrial tissue cyclic GMP (Control: 28.1 ± 
1.60 fmol/mg vs. Candoxatril: 44.5 ± 12.28 fmol/mg, p = 0.034) as well as that of plasma cyclic 
GMP (Control: 32 ± 5.5 vs. Candoxatril: 42 ± 7.1 pg/ml, p = 0.028).                            
Conclusion
               Candoxatril  suppressed the shortening of atrial  effective  refractory period and 
monophasic action potential duration in the rapid atrial pacing model.  As plasma ANP and the 
atrial tissue levels of cyclic GMP were higher in the Candoxatril group than the control, this 
effect was considered to appear through the reduction of calcium overload caused by ANP and 
cyclic GMP. 
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Introduction
            Atrial fibrillation (AF) is a common arrhythmia, especially in elderly individuals with 
cardiac disorders.   Atrial electrical remodeling, characterized by shortening of the effective 
refractory period (ERP) and decreased conduction velocity, is considered to play an important 
role in the development of the AF substrate1.  According to several reports, intracellular calcium 
overload seems to be the initial key to promote atrial electrical remodeling, especially in its 
early phase, and several interventions reducing calcium overload, such as the L-type calcium 
blocker and the sodium channel blocker, have been shown to prevent the initial phase of atrial 
electrical   remodeling2-5.                                                                  
            We have previously reported that human atrial natriuretic peptide (hANP) suppresses the 
early phase of atrial electrical remodeling in a canine rapid atrial pacing model6. Atrial 
natriuretic peptide (ANP) is produced principally in the atrium and is secreted in response to 
mechanical strain on the heart muscle.   It is reported that actions of ANP are mediated by 
increase in intracellular cyclic GMP after ANP binding to its guanylate cyclase-linked cell 
surface receptors7,8. Elevation in cyclic GMP decreases myocyte contraction, and this effect is 
mainly mediated through the cyclic GMP-dependent protein kinase and can reduce intracellular 
calcium9,10.  Therefore ANP would be expected to suppress the calcium overload through the 
action of cyclic GMP signaling.  Although this preventive effect of ANP against the initiation of 
atrial electrical remodeling is considered reasonable to maintain homeostasis, ANP has a 
significant limitation in clinical use because it cannot be orally administered. In this study, the 
effect of candoxatril (Cx), a neutral endopeptidase inhibitor (NEPI), on atrial electrical 
remodeling was studied. 　Because neutral endopeptidase is a membrane-bound metalloenzyme 
that cleaves endogenous peptide such as ANP11,12, we hypothesized that oral administration of 
Cx would potentiate the role of endogenous ANP and suppress the electrical remodeling.     
Methods
Subjects   and   preparation                                                                                  
            Ten beagle dogs weighing 12.5 to 22.1 kg were used for this study, and the preparation 
followed our previous reports13-15.  Initial anesthesia was made with an intravenous injection of 
pentobarbital (25 mg/kg), and it was kept with an additional administration of pentobarbital (3 
mg/kg/hr) after intubation and mechanical ventilation (Harvard Inc., Boston, MA, USA).  Tidal 
volume and oxygen concentration were adjusted to maintain arterial pH between 7.35 and 7.45, 
and the heart was exposed via a right thoracotomy.  After an 8F sheath was placed in the right 
femoral vein, a radiofrequency ablation catheter was inserted and the His bundle was ablated to 
avoid rapid ventricular response during rapid atrial pacing (Marinr MC, 4mm tip, 7F and Atakr, 
Medtronic Japan Inc, Tokyo, Japan).   After His bundle ablation, the ventricular rate was 
maintained by epicardial ventricular pacing at 100 beats per minute (THERA SR-i 8960i 
Medtronic Japan Inc., Tokyo, Japan).  Systemic blood pressure was monitored continuously 
from the femoral artery, and central venous pressure and pulmonary capillary wedge pressure 
were measured by a Swan-Ganz catheter introduced through the femoral vein.   A pair of 
stainless steel wire electrodes was fixed at the epicardial surface of the right atrial appendage 
(RAA), and this was used for continuous rapid atrial pacing.  Two pairs of platinum plunge-wire 
electrodes were fixed at the right atrial surface of the pectinate muscle and were used to evaluate 
the atrial effective refractory period (AERP) and the monophasic action potential duration 
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(MAPD).   In this study, we used hook-shaped customized needle-electrodes for pacing and 
recording16.   They were punctured on the surface of the RAA and sutured to keep secured 
position.  All studies were performed in accordance with the guidelines specified by the Animal 
Experimentation and Ethics Committee of Kitasato University School of Medicine.                 
Drug   administration                                                                      
            Candoxatril (Cx; Pfizer Co., Ltd., London, GB) was used as a neutral endopeptidase 
inhibitor in this study.  In 5 of 10 dogs, 24 mg/kg of Cx at 12 hours and 20 mg/kg of Cx at 2 
hours before the experiment were orally preadministered (Cx group).   Because Cx is not 
commercially available and the amount of it was totally limited, only single dose of Cx which 
concentration in plasma could not be measured was examined. But a proper dose of Cx was 
determined from the previous report17 to achieve plasma levels of inhibitor exceeding IC95 that 
is   the   concentration   at   which   95   %   of   biological   activity   is   inhibited   throughout   the 
experiments.  The remaining 5 dogs without Cx administration were evaluated as the control.
Pacing protocol and electrophysiological measurement                                                     
            After the initial surgical procedure, the dogs were allowed to recover for 60 minutes to 
achieve a stable state, and AERP and MAPD were evaluated for three different basic cycle 
lengths (BCL), i.e., 300, 200 and 150 ms.  Continuous rapid atrial pacing from RAA at 400 
beats per minute was then started and continued for 6 hours (SEN-7203, Nihon-Kohden Co., 
Tokyo, Japan), and AERP and MAPD were re-evaluated after this 6-hour pacing. In the 
electrophysiological evaluation, stimulus was delivered at an output twice the diastolic threshold 
with a 2 ms rectangular pulse, the coupling interval of the extrastimulus was shortened by a 2 
ms step, and the longest coupling interval which failed to capture the atrium was defined as 
AERP.  For the evaluation of MAPD, the interval between peak deflection and the 20% or 90% 
recovery point of the MAP trace was measured, i.e., MAP20 and MAP90, respectively.  In this 
study, we did not evaluate other parameters of the electrical remodeling such as the conduction 
time and the inducibility of AF.  Because early phase of the electrical remodeling is assumed to 
recover   in   short   term18,   complicated   protocol   could   cause   the   distrust   of   accuracy.  
               The surface ECG and atrial electrogram were amplified using a polygraph system 
(Polygraph 365, NEC Inc., Tokyo, Japan).   These analog signals were converted to digital 
signals with a sampling frequency of 1000 Hz (Power Lab 8 sp, Bioresearch Co., Ltd., Tokyo, 
Japan) and stored on a computer.  The band-pass filter was set at 50-300 Hz for the standard 
cardiac electrogram and open-300 Hz for MAP recording.                                             
Biochemical analysis of neuro-endocrinal factors and cyclic GMP                                 
            A blood sample was taken from the femoral artery before and after the rapid atrial pacing 
protocol to assay the plasma levels of neuro-endocrinal factors and cyclic GMP.  ANP, renin 
activity,  angiotensin II (Ang II), aldosterone and cyclic GMP were measured  by radio 
immunoassays (Sumikin Bio-Science Inc., Japan).  Right atrial tissue was excised at the end of 
the whole protocol, frozen in liquid nitrogen and stored at -80 °C to measure myocardial cyclic 
GMP.   Using a purified atrial tissue extract, an enzyme-immunoassay for cyclic GMP was 
performed according to the manufacturer’s protocol (Amersham Biosciences, Corp. USA.).     
Statistical   analysis                                                          
            Values are presented as the mean ± SD.  A paired t-test was used for the continuous 
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values and ANOVA was used for comparison between groups of discrete variables.  Statistical 
significance   was   defined   as   P<0.05.                                                                
Results
Hemodynamics
              Table 1 shows the hemodynamic parameters during the study protocol. Significant 
differences did not appear during the time course and there were no significant differences 
between the two groups. This indicates that NEPI did not affect the hemodynamics in this study 
protocol.
Table 1. Changes of hemodynamic findings
Atrial   effective   refractory   period   (AERP)                                                            
               AERP data are shown in  Figure 1. In the control group, AERPs were shortened 
significantly at all basic cycle lengths (BCL300: from 130 ± 7 to 120 ± 10 ms, p = 0.043, 
BCL200: from 116 ± 6 to 106 ± 7 ms, p = 0.003, BCL150: from 101 ± 12 to 88 ± 8 ms, p = 
0.022). In contrast, in the Cx group, AERP shortening was suppressed and no significant 
difference was observed before and after the rapid pacing.
Monophasic action potential duration (MAPD)                                                           
            Figure 2 shows representative MAP traces at three basic cycle lengths recorded at the 
RAA site.   In the control group, MAP traces showed relatively obvious shortening in their 
durations at all basic cycle lengths after the rapid pacing protocol, but there was no change in 
the Cx group.  Figure 3 shows MAPD data, i.e., MAP20 and MAP90, calculated from the MAP 
traces.  Although the change showed significance only in MAP90 at 300 ms BCL (from 177 ± 
13 to 143 ± 12 ms, p = 0.021), MAPD tended to be shortened in the control group. In contrast, 
in the Cx group, no MAPD change tendencies were observed. 
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Figure 1.  Changes in AERPs from a rapid pacing protocol.   In the control group, AERPs were shortened 
significantly by rapid atrial pacing at all basic cycle lengths (BCLs).  In contrast, in the candoxatril group, this 
AERP shortening was suppressed and no significant difference was observed.  See text for discussion. * p<0.05, 
NS: not significant.
Figure 2. Representative traces of the monophasic action potential (MAP) of atrial electrograms.  The upper panels 
show the traces in the control group and the lower panels show those in the candoxatril group.  In each panel, the 
solid trace shows the recording at baseline (0 hr) and the gray line indicates the recording after 6 hr rapid pacing.  
The horizontal bars indicate the measurement points of MAP20 and MAP90, respectively.  The shortening of the 
MAP duration was relatively obvious in the control group, whereas the change seemed to be much smaller in the 
candoxatril group.  See text for discussion. BCL: basic cycle length.
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Figure 3. Changes in MAP20 and MAP90.  The upper panel shows the MAPD data in the control group and the 
lower panel shows those in the candoxatril (Cx) group.  Although the change demonstrated significance only in 
MAP90 at 300 ms basic cycle length (BCL), MAPD tended to be shortened in the control group.  In contrast, in the 
Cx group, no MAPD change tendency was observed.  See text for discussion.* P<0.05
Levels of neuro-endocrinal factors and cyclic GMP                                                         
            Changes in plasma concentrations of ANP, cyclic GMP, renin activity, Ang II and 
aldosterone are shown in Figure 4. The plasma level of ANP was significantly increased by 
rapid pacing in both groups (control: from 25.6 ± 9.05 to 88.4 ± 50.25 pg/ml, p = 0.033, Cx: 
from 75.8 ± 48.63 to 197.1 ± 32.09 pg/ml, p = 0.014), and that of after rapid pacing was higher 
in the Cx group than the control (88.4 ± 50.25 vs. 197.1 ± 32.09 pg/ml p = 0.004). There was no 
difference between the two groups in renin activity and angiotensin II levels. The plasma level 
of aldosterone was increased in the control group (from 61 ± 63.2 to 256 ± 133.1 pg/ml, p = 
0.028), but not in the Cx group after rapid pacing (from 32 ± 26.4 to 40 ± 20.6 pg/ml, p = 
0.753).
            On the other hand, the plasma level of cyclic GMP was not changed significantly by 
rapid pacing, but the level was higher in the Cx group than the control (baseline: 32 ± 5.5 vs. 42 
± 7.1 pg/ml, p = 0.028, after rapid pacing: 34 ± 9.9 vs. 48 ± 10.2 pg/ml, p = 0.048).  
Additionally, the level of cyclic GMP in the extract of the right atrial myocardium was 
significantly higher in the Cx group than the control after rapid pacing (28.1 ± 1.60 vs. 44.5 ± 
12.28 fmol/mg, p = 0.034) (Figure 5).
Discussion
            In this study evaluating the effect of Cx on atrial electrical remodeling in a canine rapid 
atrial pacing model, we noted several interesting findings: First, AERP shortening caused by 
rapid pacing was suppressed by Cx administration; second, there was no significant change in 
the hemodynamics; third, the plasma and tissue levels of cyclic GMP were higher in the Cx 
group than the control.  Finally, there was no significant change in the markers of the renin-
angiotensin system in the circulating blood although an increase in aldosterone was observed 
after rapid pacing only in the control group.
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Figure 4. Changes in plasma concentrations of (a) ANP, (b) cyclic GMP, (c) renin activity, (d) angiotensin II and 
(e) aldosterone.  The ANP level was significantly increased by rapid pacing in both groups, and that of after the 
rapid pacing was higher in the Cx group than the control.  The level of cyclic GMP was not changed significantly 
by rapid pacing, but the level was higher in the Cx group than the control.  There was no difference between the 
two groups in renin activity and angiotensin II levels.  The level of aldosterone was increased in the control group 
but not in the Cx group.  See text for discussion.* p<0.05
Figure 5. The level of tissue cyclic GMP after rapid pacing in the right atrial myocardium was significantly higher 
in the Cx group than the control.  See text for discussion.* p<0.05
Effect   of   Cx   on   hemodynamics                                                                        
            Although Cx administration enhanced the plasma level of ANP which was known to 
improve the hemodynamics in the condition of heart failure, there was no significant difference 
in this study.  It is unclear why increased ANP did not cause any changes in the hemodynamics, 
but there were two conceivable reasons.  One is that because the effect of ANP has been usually 
documented in diseased hearts, its effect may be small in the normal hemodynamic condition as 
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it was in this study.   In our previous study in which we demonstrated that intravenous 
administration of ANP suppressed the atrial electrical remodeling, there was also no change in 
the hemodynamics6.  Another reason is that as neutral endopeptidase catalyzes the degradation 
of a number of endogenous vasodilator peptides, e.g., ANP, as well as vasoconstrictor peptides, 
such as Ang II or endothelin-1, the physiological action of NEPI in vivo depends on the effects 
of such vasodilating and/or vasoconstricting peptides.  Actually, the effect of Cx, i.e., NEPI, on 
hemodynamics is controversial. Several reports have documented no change, a decrease or an 
increase in blood pressure in normotensive and/or hypertensive human subjects in response to 
NEPI19-23.  In the present study, Cx produced no hemodynamic changes while it suppressed the 
increase in aldosterone concentration that was seen in control dogs.  This indicates that Cx did 
not affect the hemodynamics, at least in this short-term electrical remodeling model, and the 
suppressive effect of Cx on AERP shortening is not considered to result from its effect on 
hemodynamics.
Suppressive effect of Cx on electrical remodeling                                                                     
            In this study, Cx suppressed AERP shortening caused by rapid pacing in comparison 
with the control.  Therefore, NEPI is considered to prevent atrial electrical remodeling, at least 
in its early phase.  As the level of ANP was significantly higher in the Cx group than the control, 
this result seems compatible with our previous work, which documented the suppressive effect 
of hANP on the early phase of atrial electrical remodeling6.                               
            The mechanism of the suppressive effect of Cx (NPEI) on electrical remodeling is 
uncertain, but the signaling of cyclic GMP may play an important role.  Several reports have 
documented that natriuretic peptides, including ANP and C-type, would increase intracellular 
cyclic GMP resulting in the accelerated phosphorylation of phospholamban24-27. This activates 
calcium-ATPase in the sarcoplasmic reticulum (SERCA), and the re-absorption of calcium to 
the sarcoplasmic reticulum (SR) increases, resulting in reduced intracellular calcium overload. 
As calcium overload is considered an important key to initiate electrical remodeling, especially 
in its early phase, this mechanism may explain the suppressive effect of Cx on AERP shortening 
in our model. Although the increased degree of the plasma and atrial tissue cyclic GMP after the 
rapid pacing were smaller than that of ANP, they were increased in Cx group as compared to 
control group.  This might be the reason that the level of cyclic GMP, i.e., second messenger 
depends on not only ANP but also other factors.
Effect of Cx on the renin-angiotensin-aldosterone system
            There are some reports which have indicated that suppression of the renin-angiotensin-
aldosterone system (RAAS) may prevent atrial fibrillation, mainly through the reduction of 
myocardial fibrosis18,28. As Cx (NEPI) also inhibits the degradation of active-renin or Ang II, it 
may show an inverse effect on preventing the construction of the atrial fibrillation substrate.  
Although there was no significant difference in this study, the plasma level of Ang II was 
increased in comparison with that of active-renin in the Cx group before the pacing.   The 
mechanism of this change was unknown, but did not affect the hemodynamics at least. On the 
other hand, the plasma level of aldosterone was even higher in the control group than the Cx 
group after rapid pacing.  Some of these changes might be affected by the inhibitory action of 
ANP on the renin-angiotensin-aldosterone system29, 30, the release of aldosterone from adrenal30, 
or the expression of CYP11B2 (aldosterone synthetase)31. Meanwhile, the effect of Cx on the 
renin-angiotensin system in the myocardium was not obvious in our study, which might become 
another key in long-term electrical and structural remodeling.                                  
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Limitations
            There are several limitations in our study.  First, the number of experiments is relatively 
small.  However in this study, the dogs were carefully chosen, basing on the single species (not 
mongrel), same gender, similar body weight and age, so that the difference between individual 
should be small, therefore we think we can conclude the results of this study basing on this 
number.  Second, because pharmacological autonomic blockade was not used in this study, its 
influence on electrical remodeling could not be excluded.  It is unclear whether the autonomic 
nerve system is related to atrial electrical remodeling, but intravenous ANP in patients with a 
decompensated heart has been demonstrated to benefit cardiac sympathetic nerve activity and 
improve left ventricular remodeling32.  Third, the inhibitory effect of Cx on long-term electrical 
remodeling   is   unknown.   Because   ANP   has   additional   functions,   i.e.,   improvement   of 
hemodynamics by natriuresis and suppression of RAAS besides reduction of calcium overload 
such as verapamil, these effects might suppress the structural remodeling in chronic AF.  Since 
it is unknown how does Cx influence RAAS and the atrial electrical remodeling in long term AF 
model, this points will be evaluated with and without angiotensin-converting enzyme inhibitor 
in addition to Cx in the next study.   Fourth, we did not evaluate the electrophysiological 
properties in the left atrium. This evaluation was omitted mainly because of study time 
limitation during relatively quick recovery from the electrical remodeling with short-term, i.e., 7 
hour pacing. Finally, this study is principally the observation of the effect of Cx on the electrical 
remodeling in specific experimental condition.  Although several parameters have been changed 
simultaneously, the increases in ANP and cyclic GMP were compatible for the effect of Cx and 
the prevention of calcium overload.  According to these results, we speculated the increases in 
ANP and cyclic GMP as the explanation of the observation.  To demonstrate our hypothesis 
more  clearly,  further  study  in  which  increased   cyclic   GMP acts  independently  for the 
suppression of electrical remodeling should be examined.                                                           
Conclusion
            Cx, a NEPI, suppressed AERP shortening in a canine rapid atrial pacing model with no 
significant change in hemodynamics.  As the levels of plasma ANP, plasma and atrial tissue 
cyclic GMP were higher in the Cx group than the control, the suppressive effect of Cx on 
electrical remodeling might be appeared through the reduction of calcium overload through of 
enhanced SERCA activity.  This finding may lead to a new therapeutic modality to prevent the 
construction of an arrhythmogenic substrate, especially in patients with heart failure.              
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